Novo Nordisk losing patent rights covering Ozempic in Canada and a US Supreme Court decision favouring Ed Sheeran were also among the top talking points
Jorg Thomaier, who has been head of IP at the German pharma company since 2010, will leave later this year and hand the reins to the company’s head of patents